ReviewJournal of pharmaceutical analysis2026
Potential mechanisms of natural products in improving gouty arthritis: Focusing on NLRP3 inflammasome regulation.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gouty arthritis (GA) is a metabolic inflammatory disorder characterized by the deposition of monosodium urate crystals. Although conventional treatments like colchicine can relieve symptoms, they come with several limitations, such as gastrointestinal side effects, hepatorenal toxicity, and poor target specificity. In contrast, natural products, known for their multi-pathway and multi-target properties, present distinct advantages and significant potential for intervening in GA. The primary pathological mechanism of GA involves the overactivation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, making its regulation a promising therapeutic approach. However, there is currently a lack of comprehensive reviews on how natural products target the NLRP3 inflammasome. Additionally, existing studies have not sufficiently classified or integrated the mechanisms involved in transcriptional and translational regulation during the priming phase, post-translational modifications, and the various pathways active during the activation phase. This article aims to address these gaps through a systematic literature review, providing an in-depth analysis of the molecular mechanisms by which natural products alleviate GA by targeting the NLRP3 inflammasome. It also critically examines the major challenges in current translational research, with the objective of offering a solid theoretical foundation and practical strategies for developing novel, effective anti-inflammatory drugs and expediting the clinical application of natural products for GA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.